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We report the long-term follow up of 15 Italian patients
affected by Chronic Infantile Neurological Cutaneous and
Articular (CINCA) syndrome (7 males and 8 females,
mean age 13, 5 years).
We report the updating of the survey following the intro-
duction of the IL-1 receptor antagonist therapy (Anak-
inra).
11 patients were treated with subcutaneous injections, at
a daily dosage of 1 mg/Kg in children and up to 100 mg
in adults, 2 refused the therapy, and the others did not
require the treatment due to a mild presentation of the
disease so far.
In treated patients fever, rash, articular involvement, con-
junctivitis, uveitis disappeared or improved. Laboratory
data normalized in most of the cases within the first
month. The neurologic symptoms ameliorated, papille-
dema disappeared in four out of eleven treated patients
while dysmorphisms (typical facies) and bone alterations
constantly persist. No further Cinca related signs and
symptoms appeared after Anakinra was introduced.
The medication showed very good tolerability: we
observed local erythema at the site of injection in 2 out of
11 subjects, and oral aphtosys in another.
The untreated subjects kept presenting all their symptoms
of CINCA syndrome and the disease went on with its poor
manifestation. We found no differences in the response to
Anakinra therapy between CIAS1-mutated and not
mutated patients.
In summary, our study demonstrates that a long lasting
treatment with Anakinra appears to be safe and highly
effective in patients affected by CINCA syndrome.
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